got it
Artrya's core proprietary solution Salix has been admitted by the Thereapeutic Good Administration (TGA) as a Class 1 product, meaning it is free to be commercialised and licensed in Australia.
The funds from the IPO will go towards further research and development, as well as supporting international expansion in 2022 with regulatory approval applications already filed with the US Food and Drug Administration (FDA), with other regulatory filings to be made in the near future in Canada, the EU and the UK.
IPO - Artrya Limited - 26 November 2021 12:30 PM AEDT##, page-6
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AYA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.030(9.38%) |
Mkt cap ! $22.82M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 30.0¢ | 29.0¢ | $3.077K | 10.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1754 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 27383 | 2 |
View Market Depth
| Last trade - 14.04pm 30/08/2024 (20 minute delay) ? |
| AYA (ASX) Chart |